Life Sciences Tools and Services

INSILICO

Suzhou Rebiotek Biotechnology and Insilico Medicine Reach Strategic Partnership for AI-Driven siRNA Drug Development

InSilico Medicine and RiboBio Deepen Strategic Cooperation to Enhance Small Interfering RNA Drug Development Efficiency

Insilico Medicine Collaborates with Google Cloud to Accelerate Drug Discovery

InSilico Medicine Buys Over 105 Million USD in Wealth Management Products Using Internal Funds

AI Drug Companies Secure Funding and Enter Clinical Trials

Insilico Medicine's Rentosertib Inhalation Solution Approved by China's NMPA for Clinical Trials

Insilico Medicine Nominates ISM0387 as UAE's First Preclinical Candidate Drug

Insilico Medicine Nominates ISM0387 as a Preclinical Candidate for Glioblastoma Treatment

InSilico Medicine Advances Drug Discovery with AI Platform Pharma.AI

Tigermed and Insilico Medicine Sign Strategic Partnership on AI-Driven Drug R&D

InSilico Medicine Grants Qualified Individuals 3.7069 Million Restricted Share Units

CICC First Coverage of Insilico Medicine with Outperform Industry Rating

INSILICO released FY2025 9 Months Earnings on March 29 Post-Market (BJT), actual revenue HKD 326.56 M, actual EPS HKD -18.1359

INSILICO released FY2025 Q4 earnings on March 29 (BJT), actual revenue HKD 111.96 M, actual EPS HKD -16.1762

INSILICO released FY2025 Annual Earnings on March 29 (BJT), actual revenue HKD 438.54 M (forecast HKD 429.27 M), actual EPS HKD -34.9338 (forecast HKD 0)

INSILICO released FY2025 Q3 earnings on March 29, 2026 (BJT), actual revenue HKD 112 M, actual EPS HKD -16.1823

Insilico Medicine Announces FY2025 Loss Widened to $352 Million

Insilico Medicine Announces First Annual Results Post-IPO

Insilico Medicine and Yuan Yi Biopharma Enter into $94.75 Million AI-Driven R&D Collaboration

Insilico Medicine Expands AI-driven Neurological Disease Collaboration with Tennessee Biotech

FAMEGLOW

HAICHANG HLDG

NEW GONOW RV

ZHONGSHENJIANYE

TJCD

ZXZN QI-HOUSE

INTELLIMARK W27

EASYHOLD GROUP

CH CITY INFRA

51WORLD

03696

Insilico Medicine has received IND clearance for its Rentosertib inhalation solution, marking it as the first AI-driven candidate to enter direct-to-lung clinical studies. This follows positive Phase IIa results for oral Rentosertib, demonstrating good tolerability and efficacy. The inhalation solution aims for targeted lung delivery, enhancing bioavailability while minimizing systemic exposure. The upcoming Phase I study will assess safety and pharmacokinetics in healthy participants and IPF patients. This clearance highlights Insilico's advancements in AI-driven drug discovery, with 13 programs now receiving IND approval.

prnewswire

Eli Lilly

ASKA Pharmaceutical Holdings Co., Ltd.

FOSUN PHARMA

Sanofi

21:00 ETInsilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

InSilico Medicine has received Investigational New Drug approval from China's Center for Drug Evaluation for its inhaled solution Rentosertib, aimed at treating idiopathic pulmonary fibrosis. This is the 13th program from its AI-driven pipeline to reach clinical trials, highlighting the effectiveness of its Pharma.AI platform. The approval allows for a Phase I trial involving 80 subjects. Rentosertib, a small-molecule TNIK inhibitor, holds U.S. Orphan Drug and China Breakthrough Therapy Designations, potentially enhancing InSilico's position in AI-enabled drug discovery.

Tip Ranks

InSilico Medicine Wins China IND Nod for AI-Discovered IPF Drug Rentosertib

Insilico Medicine has nominated ISM0387 as the UAE's first preclinical candidate, marking a significant milestone in local drug discovery. This achievement, supported by the Emirates Drug Establishment and other local partners, showcases the UAE's growing capabilities in biotechnology. ISM0387, an innovative PRMT5 inhibitor, was developed using Insilico's AI-driven Pharma.AI platform, completing the discovery process in under a year. This development reflects the UAE's ambition to become a global hub for pharmaceutical innovation and enhance its position in the biotech value chain.

09:00 ETGenerative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

InSilico Medicine has announced that its UAE team has advanced ISM0387, an AI-designed brain cancer drug, to the preclinical stage. This candidate, a PRMT5 inhibitor, was developed in under 12 months and shows promise for treating glioblastoma. The achievement highlights the company's AI-driven drug discovery capabilities and its integration into Abu Dhabi's life sciences ecosystem, supported by local health and investment authorities. InSilico Medicine continues to expand its portfolio of AI-supported preclinical candidates, enhancing its competitive position in the industry.

InSilico Medicine’s UAE Team Advances AI-Designed Brain Cancer Drug to Preclinical Stage

00068

02477

02225

02427

02632

00650

02556

06682

02768

MANYCORE TECH(00068) rose 101.29%, with a trading turnover 4.0 Billion HKD, and a year-to-date rose 391.3%. WELLCELL HOLD(02477) rose 21.17%, with a trading turnover 249.9 Million HKD, and a year-to-date rose 107.6%. JINHAI MED TECH(02225) rose 19.46%, with a trading turnover 48.2 Million HKD, and a year-to-date rose 253.6%.

Top Gainers&Losers

MANYCORE TECH

WELLCELL HOLD

JINHAI MED TECH

GUANZE MEDICAL

NEW VISION CO

PRODUCTIVE TECH

MARKETINGFORCE

PHANCY

GON TECHNOLOGY

Top 10 HK Stock Gainers (4.20)

00700

01024

02513

09888

The Hong Kong stock market rose in the morning session influenced by the US stock market, with the Hang Seng Index up 216 points at 26,376 points. AI stocks performed strongly, with KNOWLEDGE ATLAS and INSILICO rising 10.6% and 15% respectively. TENCENT rose 2.6%, and other tech stocks such as Baidu, NetEase, and KUAISHOU also saw increases. The State Administration for Market Regulation imposed fines on seven e-commerce platforms, leading to slight declines for Meituan and JD.com, while Alibaba saw a slight increase. The overall market turnover was HKD 135.314 billion

AASTOCKS

TENCENT

KUAISHOU-W

KNOWLEDGE ATLAS

BIDU-SW

Hang Seng Index

Hang Seng China Enterprises Index

Hang Seng TECH Index

MINIMAX-W

UNISOUND

KINGSOFT CLOUD

GDS-SW

MEITUAN

JD-SW

BABA-W

NTES-S

SMIC

HUA HONG SEMI

SUNNY OPTICAL

Lens

AAC TECH

UBTECH ROBOTICS

ROBOSENSE

YOFC

BYD COMPANY

XIAOMI-W

LEAPMOTOR

WERIDE-W

PONY-W

CATL

CITIC BANK

MINSHENG BANK

ZA ONLINE

HSBC HOLDINGS

HKEX

PETROCHINA

CHINA SHENHUA

CHINA COAL

CHALCO

COSCO SHIP ENGY

CHINA EAST AIR

AIR CHINA

XINYI SOLAR

GCL TECH

FLAT GLASS

GOLDWIND

LI NING

SHENZHOU INTL

DAMAI ENT

MNSO

MAO GEPING

MIXUE GROUP

POP MART

GPIXEL

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Kingsoft Cloud

MEITUAN-WR

Meituan

Meituan HK SDR 5to1

JD-SWR

JD.com

Alibaba

BABA-WR

Alibaba HK SDR 5to1

BIDU-SWR

Baidu

NetEase

KUAISHOU-WR

SMIC HK SDR 5to1

Hua Hong

BYD HK SDR 10to1

BYD Company

BYD Company Limited

BYD COMPANY-R

Xiaomi Corporation

XIAOMI-WR

Xiaomi HK SDR 2to1

Pony AI

CATL HK SDR 30to1

CNCB

CMBC

HSBC 5xShortSG241213

HSBC Holdings Plc

HSBC

"Hong Kong Stocks" Hang Seng Index rises 216 points in half a day, Tencent leads the surge in AI stocks

01201

03997

Hong Kong stock market overview in the past hour: Market sentiment seems to be gradually warming up amid recent fluctuations, especially with the technology and healthcare sectors performing prominently. Capital flows are clearly favoring small-cap stocks and thematic stocks, with short-term enthusiasm rising, leading to strong rebounds in multiple individual stocks. Overall, stocks with significant gains are concentrated in the innovative technology and healthcare sectors, indicating that investor confidence in these industries is increasing. Meanwhile, the downward pressure on certain stocks also reflects the divergence in market strength, with increased volatility and active short-term trading. 

The biggest movers in the past hour: Tesson Holdings surged 21.05%, attracting market attention, with noticeable capital inflow and heightened short-term sentiment, seemingly actively drawing more investors' interest. The strong performance of this stock has also boosted the activity of related sectors, creating a positive linkage effect. 

Strong stocks: 
1. New Vision Co: Up 20.42%, recent optimistic expectations for its prospects have driven a rapid rise in its stock price, with significant short-term capital inflow.
2. TSO: Up 17.82%, this stock has performed well against the backdrop of industry recovery, attracting a large amount of short-term capital attention.
3. INSILICO: Up 16.86%, strong technical performance, with heightened market sentiment and continuous capital inflow.
4. JINHAI MED TECH: Up 16.49%, the rising enthusiasm in the healthcare sector has driven a strong rebound in this stock.
5. WELLCELL HOLD: Up 15.42%, active short-term capital, with the market full of expectations for its future development

HK Stock Alerts

TESSON HOLDINGS

BGMC International

GUOXIA TECH

RUIYUAN IC TECH

EXTREME VISION

JU FU TANG BIOT

Hong Kong Stock Movement Quick Report: Technology stocks rebound strongly, Tesson Holdings and New Vision Co rise over 20%

InSilico Medicine Cayman TopCo has granted 3,706,886 restricted share units (RSUs) to eligible employees under its Post-IPO RSU Scheme, with no purchase price based on a share price of HK$60.35. The RSUs are divided into special and regular tranches, with multi-year vesting schedules linked to performance criteria. This initiative aims to retain high-performing staff and enhance operational execution. InSilico Medicine is a Hong Kong-listed biotechnology firm focused on drug discovery and development, targeting the global pharmaceutical market.

InSilico Medicine Grants 3.7 Million RSUs to Boost Retention and Performance

INSILICO(03696.HK)